Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Kite's CAR-T Approved in China for Lymphoma

publication date: Jun 23, 2021

Fosun Kite Biotech, a Shanghai JV set up to develop Kite's CAR-T therapy in China, reported Yescarta (axicabtagene ciloleucel) was approved to treat relapsed or refractory large B-cell lymphoma. Yescarta is the first CAR-T therapy allowed to launch in China. The approval was for third-line treatment. Axicabtagene ciloleucel is an autologous CD19-directed CAR T-cell therapy manufactured in China under a license from Kite. To acquire 50% of the JV, Fosun Pharma agreed to a $95 million package that will entitle it to receive 60% of the profits. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital